Fisetin lowers methylglyoxal dependent protein glycation and limits the complications of diabetes

Pamela Maher, Richard Dargusch, Jennifer L. Ehren, Shinichi Okada, Kumar Sharma, David Schubert

Research output: Contribution to journalArticle

95 Citations (Scopus)

Abstract

The elevated glycation of macromolecules by the reactive dicarbonyl and α-oxoaldehyde methylglyoxal (MG) has been associated with diabetes and its complications. We have identified a rare flavone, fisetin, which increases the level and activity of glyoxalase 1, the enzyme required for the removal of MG, as well as the synthesis of its essential co-factor, glutathione. It is shown that fisetin reduces two major complications of diabetes in Akita mice, a model of type 1 diabetes. Although fisetin had no effect on the elevation of blood sugar, it reduced kidney hypertrophy and albuminuria and maintained normal levels of locomotion in the open field test. This correlated with a reduction in proteins glycated by MG in the blood, kidney and brain of fisetin-treated animals along with an increase in glyoxalase 1 enzyme activity and an elevation in the expression of the rate-limiting enzyme for the synthesis of glutathione, a co-factor for glyoxalase 1. The expression of the receptor for advanced glycation end products (RAGE), serum amyloid A and serum C-reactive protein, markers of protein oxidation, glycation and inflammation, were also increased in diabetic Akita mice and reduced by fisetin. It is concluded that fisetin lowers the elevation of MG-protein glycation that is associated with diabetes and ameliorates multiple complications of the disease. Therefore, fisetin or a synthetic derivative may have potential therapeutic use for the treatment of diabetic complications.

Original languageEnglish (US)
Article numbere21226
JournalPLoS One
Volume6
Issue number6
DOIs
StatePublished - Jun 30 2011
Externally publishedYes

Fingerprint

Pyruvaldehyde
glycation
Diabetes Complications
Medical problems
diabetes
glutathione
kidneys
Proteins
synthesis
proteins
insulin-dependent diabetes mellitus
complications (disease)
C-reactive protein
flavones
amyloid
flavone
enzymes
blood serum
hypertrophy
blood glucose

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Agricultural and Biological Sciences(all)

Cite this

Fisetin lowers methylglyoxal dependent protein glycation and limits the complications of diabetes. / Maher, Pamela; Dargusch, Richard; Ehren, Jennifer L.; Okada, Shinichi; Sharma, Kumar; Schubert, David.

In: PLoS One, Vol. 6, No. 6, e21226, 30.06.2011.

Research output: Contribution to journalArticle

Maher, Pamela ; Dargusch, Richard ; Ehren, Jennifer L. ; Okada, Shinichi ; Sharma, Kumar ; Schubert, David. / Fisetin lowers methylglyoxal dependent protein glycation and limits the complications of diabetes. In: PLoS One. 2011 ; Vol. 6, No. 6.
@article{863f34eaed69498482fca55274ea481f,
title = "Fisetin lowers methylglyoxal dependent protein glycation and limits the complications of diabetes",
abstract = "The elevated glycation of macromolecules by the reactive dicarbonyl and α-oxoaldehyde methylglyoxal (MG) has been associated with diabetes and its complications. We have identified a rare flavone, fisetin, which increases the level and activity of glyoxalase 1, the enzyme required for the removal of MG, as well as the synthesis of its essential co-factor, glutathione. It is shown that fisetin reduces two major complications of diabetes in Akita mice, a model of type 1 diabetes. Although fisetin had no effect on the elevation of blood sugar, it reduced kidney hypertrophy and albuminuria and maintained normal levels of locomotion in the open field test. This correlated with a reduction in proteins glycated by MG in the blood, kidney and brain of fisetin-treated animals along with an increase in glyoxalase 1 enzyme activity and an elevation in the expression of the rate-limiting enzyme for the synthesis of glutathione, a co-factor for glyoxalase 1. The expression of the receptor for advanced glycation end products (RAGE), serum amyloid A and serum C-reactive protein, markers of protein oxidation, glycation and inflammation, were also increased in diabetic Akita mice and reduced by fisetin. It is concluded that fisetin lowers the elevation of MG-protein glycation that is associated with diabetes and ameliorates multiple complications of the disease. Therefore, fisetin or a synthetic derivative may have potential therapeutic use for the treatment of diabetic complications.",
author = "Pamela Maher and Richard Dargusch and Ehren, {Jennifer L.} and Shinichi Okada and Kumar Sharma and David Schubert",
year = "2011",
month = "6",
day = "30",
doi = "10.1371/journal.pone.0021226",
language = "English (US)",
volume = "6",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "6",

}

TY - JOUR

T1 - Fisetin lowers methylglyoxal dependent protein glycation and limits the complications of diabetes

AU - Maher, Pamela

AU - Dargusch, Richard

AU - Ehren, Jennifer L.

AU - Okada, Shinichi

AU - Sharma, Kumar

AU - Schubert, David

PY - 2011/6/30

Y1 - 2011/6/30

N2 - The elevated glycation of macromolecules by the reactive dicarbonyl and α-oxoaldehyde methylglyoxal (MG) has been associated with diabetes and its complications. We have identified a rare flavone, fisetin, which increases the level and activity of glyoxalase 1, the enzyme required for the removal of MG, as well as the synthesis of its essential co-factor, glutathione. It is shown that fisetin reduces two major complications of diabetes in Akita mice, a model of type 1 diabetes. Although fisetin had no effect on the elevation of blood sugar, it reduced kidney hypertrophy and albuminuria and maintained normal levels of locomotion in the open field test. This correlated with a reduction in proteins glycated by MG in the blood, kidney and brain of fisetin-treated animals along with an increase in glyoxalase 1 enzyme activity and an elevation in the expression of the rate-limiting enzyme for the synthesis of glutathione, a co-factor for glyoxalase 1. The expression of the receptor for advanced glycation end products (RAGE), serum amyloid A and serum C-reactive protein, markers of protein oxidation, glycation and inflammation, were also increased in diabetic Akita mice and reduced by fisetin. It is concluded that fisetin lowers the elevation of MG-protein glycation that is associated with diabetes and ameliorates multiple complications of the disease. Therefore, fisetin or a synthetic derivative may have potential therapeutic use for the treatment of diabetic complications.

AB - The elevated glycation of macromolecules by the reactive dicarbonyl and α-oxoaldehyde methylglyoxal (MG) has been associated with diabetes and its complications. We have identified a rare flavone, fisetin, which increases the level and activity of glyoxalase 1, the enzyme required for the removal of MG, as well as the synthesis of its essential co-factor, glutathione. It is shown that fisetin reduces two major complications of diabetes in Akita mice, a model of type 1 diabetes. Although fisetin had no effect on the elevation of blood sugar, it reduced kidney hypertrophy and albuminuria and maintained normal levels of locomotion in the open field test. This correlated with a reduction in proteins glycated by MG in the blood, kidney and brain of fisetin-treated animals along with an increase in glyoxalase 1 enzyme activity and an elevation in the expression of the rate-limiting enzyme for the synthesis of glutathione, a co-factor for glyoxalase 1. The expression of the receptor for advanced glycation end products (RAGE), serum amyloid A and serum C-reactive protein, markers of protein oxidation, glycation and inflammation, were also increased in diabetic Akita mice and reduced by fisetin. It is concluded that fisetin lowers the elevation of MG-protein glycation that is associated with diabetes and ameliorates multiple complications of the disease. Therefore, fisetin or a synthetic derivative may have potential therapeutic use for the treatment of diabetic complications.

UR - http://www.scopus.com/inward/record.url?scp=79959596092&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79959596092&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0021226

DO - 10.1371/journal.pone.0021226

M3 - Article

C2 - 21738623

AN - SCOPUS:79959596092

VL - 6

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 6

M1 - e21226

ER -